



INDO-BANGLA PHARMACEUTICALS LIMITED

PLOT # 183 (7th FLOOR), BLOCK # B, AHMED AKBER SOBHAN ROAD,
BASHUNDHARA R/A, Dhaka-1229.

PRICE SENSITIVE INFORMATION

This is for kind information that, the Board of Directors of Indo-Bangla Pharmaceuticals Limited (“Company”) in its meeting held on **Tuesday 30th April, 2024 at 3:30 p.m.** at the corporate office, has approved the Un-Audited Financial Statements for the Third Quarter (Q3) period ended on 31th March, 2024.

The key financial highlights for the Third Quarter ended 31th March, 2024 are appended below:

SL No.	Particulars	9 months		3 months	
		July to March		January to March	
		2023-2024	2022-2023	2023-2024	2022-2023
1.	Earnings Per Share (EPS)	(0.13)	0.10	(0.08)	0.01
2.	Net Operating Cash Flows Per Share (NOCFPS)	0.19	0.06	-	-
		As at 31st March, 2024		As at 30th June, 2023	
3.	Net Asset Value (NAV) per share	13.83		13.96	

By order of the Board of Directors

-sd-

(Mohi Uddin)

Company Secretary

The details of the published Third Quarter (Q3) Financial Statements are available in the website of the company: www.indo-banglapharma.com.